投融资数据库
免费查数据
注册送3天会员
首页>投融资
Kriya Therapeutics
D轮
Kriya Therapeutics is a next-generation gene therapy company focused on designing and developing transformative gene therapies for highly prevalent serious chronic diseases.In November 2022, Kriya Therapeutics acquired Redpin Therapeutics Inc.In January 2022, Kriya Therapeutics Inc acquired Warden Bio.In July 2023, Kriya Therapeutics Inc announced the addition of over $150 million in capital committed as part of its Series C Financing, bringing the total Series C round to $430 million.In May 2022, Kriya Therapeutics announced a $270 Million Series C financing led by Patient Square Capital, with participation from Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, JDRF T1D Fund, Lightswitch Capital, Narya Capital, QVT, Transhuman Capital, and other undisclosed investors.In May 2020, the company raised $80.5 million in a series A financing
基本信息
-
公司全称Kriya Therapeutics Inc
-
类型基因治疗新药研发商
-
产业领域医药研发/制造、化学&生物药
-
公司人数15人以下
-
地址1100 Island Drive Suite 203 REDWOOD CITY CALIFORNIA 94065; US; Telephone: +18335749289;
-
联系电话1-833-574-9289
-
邮箱info@kriyatherapeutics.com
-
成立时间2019-01-01
投融资
-
2025-09-10
-
2025-08-16
-
2023-07-26
-
2022-05-16
-
2021-07-14
-
2020-05-12
-
2019-12-01
- 加载更多
相关投融资企业
A轮
Engitix LIMITED is a biopharmaceutical company that focuses on the development of therapeutics.In January 2022, Engitix Ltd announced the close of its $54m Series A financing as well as a strategic collaboration with Dompé farmaceutici S.P.A
收并购
Agenus Inc.是一家致力于开发和商业化治疗癌症和传染病疗法的生物技术公司，且主要是基于免疫学疗法。公司的技术组合由 Saponin Platform和Heat Shock Protein Platform组成。在其皂素平台包括QS-21 Stimulon佐剂或QS-21 Stimulon，正处于试验阶段，可用于治疗癌症、带状疱疹、疟疾、阿尔茨海默病、人类免疫缺陷病毒和结核。在HSP平台中正在开发重组系列及前噬菌体系列疫苗。重组系列平台的HerpV疫苗包含了QS-21 Stimulon，可用于治疗生殖器疱疹，已完成了第一阶段试验，正在进行第二阶段试验。在前噬菌体系列中，候选产品已经完成了第3期的临床试验，可用于治疗肾细胞癌。前噬菌体系列中R-100疫苗已在俄罗斯注册，用于治疗患有肾细胞癌的中期患者。此外,前噬菌体系列的g - 100和g - 200疫苗的第二阶段试验已被美国计入测试，可用于治疗神经胶质瘤的反复发作。公司的业务活动包括产品研发、知识产权诉讼、制造、管理和临床事务、企业融资和发展活动、市场开发和支持性合作。公司的候选产品需要临床试验，并经过监管机构的批准,以及市场的接受。公司部分战略是主要通过与学者、企业合作伙伴和授权人共同合作，将候选产品开发并商业化。
该公司最初作为一家特拉华州有限责任公司成立于1994年。
收并购
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases based on repeatome.In September 2021, ROME Therapeutics completed a $77 million Series B financing led by Section 32.By April 2020, the company had raised $50 million in Series A funding
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息